Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. (Q35964114)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Paul J Hesketh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Jorn Herrstedt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Cynthia Rittenberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Lawrence H Einhorn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Steven Grunberg

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Jim Koeller

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ian Olver

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Sussanne Borjeson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Enzo Ballatori

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

23 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

Supportive Care in Cancer

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

85-96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15565277%20AND%20SRC:MED&resulttype=core&format=json

Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0699-X

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0699-X

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0699-X

A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0699-X

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0699-X

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-004-0699-X

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

12 December 2020

Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group

1 reference

12 December 2020

Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis

1 reference

12 December 2020

GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis

1 reference

12 December 2020

A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group

1 reference

12 December 2020

Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer

1 reference

12 December 2020

Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study

1 reference

12 December 2020

Acute and Delayed Emesis after Cisplatin-Based Regimen: Description and Prevention

1 reference

12 December 2020

The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis

1 reference

12 December 2020

New perspectives in antiemetic treatment

1 reference

12 December 2020

Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.

1 reference

12 December 2020

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical

1 reference

12 December 2020

Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research

1 reference

12 December 2020

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

12 December 2020

Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy

1 reference

12 December 2020

Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

1 reference

12 December 2020

A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis

1 reference

12 December 2020

Control of chemotherapy-induced emesis

1 reference

12 December 2020

Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo

1 reference

12 December 2020

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

1 reference

12 December 2020

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

1 reference

12 December 2020

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

12 December 2020

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group

1 reference

12 December 2020

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained

1 reference

12 December 2020

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

1 reference

12 December 2020

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer

1 reference

12 December 2020

Delayed emesis following anticancer chemotherapy

1 reference

12 December 2020

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

1 reference

12 December 2020

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

1 reference

12 December 2020

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

12 December 2020

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

12 December 2020

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

12 December 2020

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH)

1 reference

12 December 2020

Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study

1 reference

12 December 2020

Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis

1 reference

12 December 2020

Delayed emesis: incidence, pattern, prognostic factors and optimal treatment

1 reference

12 December 2020

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group

1 reference

12 December 2020

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994

1 reference

12 December 2020

Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients

1 reference

12 December 2020

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

12 December 2020

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

1 reference

12 December 2020

Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center

1 reference

12 December 2020

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

1 reference

12 December 2020

Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research

1 reference

12 December 2020

Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

12 December 2020

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

The management of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin

1 reference

12 December 2020

Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research

1 reference

12 December 2020

Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research

1 reference

12 December 2020

Serotonin antagonists in the management of cisplatin-induced emesis

1 reference

12 December 2020

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

12 December 2020

Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis

1 reference

12 December 2020

Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone

1 reference

12 December 2020

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration

1 reference

12 December 2020

Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis

1 reference

12 December 2020

A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group

1 reference

12 December 2020

Serotonin antagonists: a new class of antiemetic agents

1 reference

12 December 2020

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

1 reference

12 December 2020

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

12 December 2020

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

1 reference

12 December 2020